Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for CPP-115

Catalyst Pharmaceutical Partners, Inc.
CPRX
today announced that the European Commission has granted orphan medicinal product designation for the company's investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, for the treatment of West Syndrome (infantile spasms). The EC designation is based on the recommendation by the European Medicines Agency (
EMA
) Committee on Orphan Medicinal Products after their review of all relevant preclinical data for CPP-115, which showed that it may have a longer duration of action, improved benefits and fewer retinal side effects than the existing first-line treatment.
Loading...
Loading...
COMP Logo
COMPCompass Inc
$6.502.60%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
89.15
Growth
49.22
Quality
Not Available
Value
34.34
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...